Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms

NIKE Group

Research output: Contribution to journalReview article

Abstract

In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multitarget tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by Regulatory Agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in-depth review on the studies published on the MTKIs in neuroendocrine tumors such as axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed. Furthermore, we extensively searched on the Clinical Trial Registries databases worldwide, in order to collect information on the ongoing clinical trials related to this topic. Our systematic analysis on emerging MTKIs in the treatment of gastroenteropancreatic and lung NENs identifies in vitro and in vivo studies, which demonstrate anti-tumor activity of diverse MTKIs on neuroendocrine cells and tumors. Moreover, for the first time in the literature, we report an updated view concerning the upcoming clinical trials in this field: presently, phase I, II and III clinical trials are ongoing and will include, overall, a staggering 1667 patients. This fervid activity underlines the increasing interest of the scientific community in the use of emerging MTKIs in NEN treatment.

Original languageEnglish
Pages (from-to)R453-R466
JournalEndocrine-Related Cancer
Volume25
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Protein-Tyrosine Kinases
Neuroendocrine Tumors
Clinical Trials
Neoplasms
Neuroendocrine Cells
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Therapeutics
Pancreatic Neoplasms
Registries
Lung Neoplasms
Databases

Keywords

  • Neuroendocrine tumors
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. / NIKE Group.

In: Endocrine-Related Cancer, Vol. 25, No. 9, 01.09.2018, p. R453-R466.

Research output: Contribution to journalReview article

@article{33dc17a0e19144d0ac5cb3fcfb76f371,
title = "Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms",
abstract = "In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multitarget tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by Regulatory Agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in-depth review on the studies published on the MTKIs in neuroendocrine tumors such as axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed. Furthermore, we extensively searched on the Clinical Trial Registries databases worldwide, in order to collect information on the ongoing clinical trials related to this topic. Our systematic analysis on emerging MTKIs in the treatment of gastroenteropancreatic and lung NENs identifies in vitro and in vivo studies, which demonstrate anti-tumor activity of diverse MTKIs on neuroendocrine cells and tumors. Moreover, for the first time in the literature, we report an updated view concerning the upcoming clinical trials in this field: presently, phase I, II and III clinical trials are ongoing and will include, overall, a staggering 1667 patients. This fervid activity underlines the increasing interest of the scientific community in the use of emerging MTKIs in NEN treatment.",
keywords = "Neuroendocrine tumors, Tyrosine kinase inhibitors",
author = "{NIKE Group} and Federica Grillo and Tullio Florio and Francesco Ferra{\`u} and Elda Kara and Giuseppe Fanciulli and Antongiulio Faggiano and Annamaria Colao",
year = "2018",
month = "9",
day = "1",
doi = "10.1530/ERC-17-0531",
language = "English",
volume = "25",
pages = "R453--R466",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "9",

}

TY - JOUR

T1 - Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms

AU - NIKE Group

AU - Grillo, Federica

AU - Florio, Tullio

AU - Ferraù, Francesco

AU - Kara, Elda

AU - Fanciulli, Giuseppe

AU - Faggiano, Antongiulio

AU - Colao, Annamaria

PY - 2018/9/1

Y1 - 2018/9/1

N2 - In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multitarget tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by Regulatory Agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in-depth review on the studies published on the MTKIs in neuroendocrine tumors such as axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed. Furthermore, we extensively searched on the Clinical Trial Registries databases worldwide, in order to collect information on the ongoing clinical trials related to this topic. Our systematic analysis on emerging MTKIs in the treatment of gastroenteropancreatic and lung NENs identifies in vitro and in vivo studies, which demonstrate anti-tumor activity of diverse MTKIs on neuroendocrine cells and tumors. Moreover, for the first time in the literature, we report an updated view concerning the upcoming clinical trials in this field: presently, phase I, II and III clinical trials are ongoing and will include, overall, a staggering 1667 patients. This fervid activity underlines the increasing interest of the scientific community in the use of emerging MTKIs in NEN treatment.

AB - In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multitarget tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by Regulatory Agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in-depth review on the studies published on the MTKIs in neuroendocrine tumors such as axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed. Furthermore, we extensively searched on the Clinical Trial Registries databases worldwide, in order to collect information on the ongoing clinical trials related to this topic. Our systematic analysis on emerging MTKIs in the treatment of gastroenteropancreatic and lung NENs identifies in vitro and in vivo studies, which demonstrate anti-tumor activity of diverse MTKIs on neuroendocrine cells and tumors. Moreover, for the first time in the literature, we report an updated view concerning the upcoming clinical trials in this field: presently, phase I, II and III clinical trials are ongoing and will include, overall, a staggering 1667 patients. This fervid activity underlines the increasing interest of the scientific community in the use of emerging MTKIs in NEN treatment.

KW - Neuroendocrine tumors

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85051227617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051227617&partnerID=8YFLogxK

U2 - 10.1530/ERC-17-0531

DO - 10.1530/ERC-17-0531

M3 - Review article

AN - SCOPUS:85051227617

VL - 25

SP - R453-R466

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 9

ER -